[177Lu]Lu-PSMA-PET/CT enables standardised stratification through the Prostate Cancer Molecular Imaging Standardised Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISEV2) criteria by assessing PSMA expression intensity and lesion distribution: identifying miPSMA-positive lesions ensures only patients with sufficient expression are selected for RLT, while metrics such as SUVmean, SUVmax and HIT score correlate with treatment response and survival [26]. The gene discussed is FOLH1; the disease is prostate carcinoma.